For the Inventor, By the Inventor

Enter assignee name

Titusville, NJ, United States of America

Janssen Pharmaceuticals, Inc.

USPTO Granted Patents = 160

CIPO Patents = 15

EPO Patents = 71

Trademarks = 1

Forward Citations = 618

Loading Chart...

Loading Chart...

251 inventors (with patents filed for the assignee):

Andrés Avelino Trabanco-Suárez (26 out of 53 patents)

Gregor James MacDonald (25 out of 56 patents)

Jose Maria Cid-Nunez (21 out of 21 patents)

4. Jean-François Bonfanti (20 out of 44 patents)

5. Bart Rudolf Romanie Kesteleyn (20 out of 36 patents)

6. Dorothée Alice Marie-Eve Bardiot (20 out of 24 patents)

7. Arnaud Didier M Marchand (20 out of 20 patents)

8. Pierre Jean-Marie Bernard Raboisson (19 out of 178 patents)

9. Peter A Krulevitch (15 out of 85 patents)

10. Nick Foley (14 out of 33 patents)

11. James McLusky (14 out of 25 patents)

12. Jeroen Geurtsen (12 out of 12 patents)

13. Michael G Cannamela (12 out of 54 patents)

14. Guillaume Albert Jacques Duvey (11 out of 11 patents)

15. Daniel Oehlrich (11 out of 16 patents)

Core Competencies:

Recombinant Arterivirus

Alphavirus-Based Replicons

Bioconjugates

Dengue Viral Replication Inhibitors

Injection Device Trainers

Multivalent Vaccine Compositions

Patient Journey Mapping

Phosphorylated Tau Peptides

Drug Administration Devices

Immune Protection

Aticaprant

ExPEC Glycoconjugate Vaccines

160 patents: Sort by Forward Citations

1. 12503698 - GALNAC DERIVATIVES (2025-12-23),

2. 12460229 - Recombinant arterivirus replicon systems and uses thereof (2025-11-04),

3. 12431230 - Interconnection of drug administration systems (2025-09-30),

4. 12428449 - FimH mutant, compositions therewith and use thereof (2025-09-30),

5. 12419859 - Compositions and methods for the treatment of depression (2025-09-23),

6. 12331076 - Alphavirus-based replicons for administration of biotherapeutics (2025-06-17),

7. 12324855 - Method of safe administration of phosphorylated Tau peptide vaccine (2025-06-10),

8. 12297238 - FimH mutants, compositions therewith and use thereof (2025-05-13),

9. 12290563 - Production of018 bioconjugates (2025-05-06),

10. 12274742 - MDRimmunogen (2025-04-14),

11. 12239460 - Controlling operation of drug administration devices using surgical hubs (2025-03-04),

12. 12236800 - Locking member for an injection device and an injection device trainer (2025-02-25),

13. 12233121 - Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof (2025-02-25),

14. 12233118 - Multivalent vaccine compositions and uses thereof (2025-02-25),

15. 12201610 - Compositions comprising aticaprant (2025-01-21),

Janssen Pharmaceuticals, Inc. is a pharmaceutical company that specializes in developing innovative treatments and solutions for various medical conditions. They are committed to improving the health and well-being of people around the world through their research and development efforts. With a focus on cutting-edge technology and scientific advancements, Janssen Pharmaceuticals is dedicated to providing quality healthcare products to patients globally.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

160 Patents

#1 in Titusville, NJ

#120 in New Jersey

#2,396 in US

#5,023 in the World

Titusville, NJ, United States of America

Janssen Pharmaceuticals, Inc.

Forward Citations = 618

251 inventors:

Andrés Avelino Trabanco-Suárez (26 out of 53 patents)

Gregor James MacDonald (25 out of 56 patents)

Jose Maria Cid-Nunez (21 out of 21 patents)

4. Jean-François Bonfanti (20 out of 44 patents)

5. Bart Rudolf Romanie Kesteleyn (20 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…